Laddar populära aktier...
Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phas...
Xplora does not meet the 90% threshold, so delisting and forced buy-out plans are on hold unless fur...
Safello pre-announced key metrics for its Q4 2024 report due 21/02/2025.
Redeye endorses today’s news that Cephagenix has secured funding of up to EUR9m and gives an initial...
Redeye provides a brief comment on Flexion Mobile’s new agreement with King, under which Flexion Mob...
Q4e: Clean paper EBIT of ~PLN 10m Paper prices down, demand muted Fair value range of SEK 40-80 Thi...
Redeye leaves a research update following Klaria Pharma’s recent announcement of a licensing agreeme...
Xplora Technologies AS announced a public offer on September 26, 2024, to acquire all shares in Doro...
Redeye comments on Nanologica following the annonucement of a SEK8.
Redeye comments on Sivers Semiconductors following the announcement that the company will receive an...
Redeye comments on SciBase’s announcement of its preliminary results for the capital raise this morn...
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-bi...
Redeye endorses today’s news that Elicera has received an orphan drug designation in the US for ELC-...
Redeye expects a stable Q4 report from Sdiptech but with tough comparables weighing negatively.
Redeye initiates coverage of OEM International, a niche acquirer of technology trading SMEs that has...